FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Response	s)										
1. Name and Address o Sherman Matthew I	2. Issuer Name an PIERIS PHARM			- ·		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) C/O PIERIS PHAR STATE STREET, 9		LO DIO ASS	3. Date of Earliest T 10/24/2018	'ransaction (Mont	th/Day/Y	ear)		ther (specify belo	ow)	
BOSTON, MA 021		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security		2. Transaction	2A. Deemed	3. Transact	ion	4. Securi	ties Acq	5. Amount of Securities Beneficially	6.	7. Nature	
(Instr. 3)		Date	Execution Date, if	Code		(A) or D	isposed c	of (D)	Owned Following Reported	Ownership	of Indirect
		(Month/Day/Year)	(Instr. 8) (Instr. 3, 4 and 5)						Transaction(s)	Form:	Beneficial
			(Month/Day/Year)						· · · · · · · · · · · · · · · · · · ·		Ownership
										or Indirect	(Instr. 4)
							(A) or	n ·		(I)	
				Code	V	Amount	(D)	Price		(Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	ber	6. Date Exer	rcisable and	7. Title and	l	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transac	tion	of	of Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code		Derivati	Derivative (Month/Day/Year)		Underlying Secur		Security	Securities	Form of	Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securitie	rities		Securities (Instr. 5)		(Instr. 5)	Beneficially	Derivative	Ownership	
	Derivative					Acquire	d	r i i i i i i i i i i i i i i i i i i i		(Instr. 3 and 4)				2	(Instr. 4)
	Security					(A) or						0	Direct (D)		
						Dispose	d of	f					1	or Indirect	
						(D)							Transaction(s)	· /	
						(Instr. 3,						(Instr. 4)	(Instr. 4)		
						and 5)									
											Amount				
								Date	Expiration		or				
								Exercisable		Title	Number				
				Colo	x 7						of				
				Code	v	(A)	(D)				Shares				
Stock															
Option	\$ 4.46	10/24/2018		٨		20.000		<u>(1)</u>	10/24/2028	Common Stock	20.000	\$ 0	30.000	D	
(right to	\$ 4.40	10/24/2018		А		30,000		<u>11</u>	10/24/2028	Stock	30,000	\$0	30,000	D	
buy)															

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Sherman Matthew L C/O PIERIS PHARMACEUTICALS, INC.	Х							
255 STATE STREET, 9TH FLOOR BOSTON, MA 02109								

Signatures

/s/ Marc D. Mantell, Esq., Attorney-in-Fact	10/25/2018
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option will vest as to 100% of the underlying shares on October 24, 2019, subject to the Reporting Person's continued service as a director through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.